Immunotherapy for diabetic amyotrophy

10.1002/14651858.CD006521Cochrane Database of Systematic Reviews2

Hepatocellular carcinoma in Asia

Hepatocellular Carcinoma: A Global Challenge31-5

Estimating Information Processing in a Memory System: The Utility of Meta-analytic Methods for Genetics

10.1371/journal.pgen.1005718PLoS Genetics1112e100571

Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients

10.1159/000126919Cerebrovascular Diseases255450-456CDIS

A randomised controlled trial evaluating the impact of targeted Vitamin D supplementation on endothelial function in type 2 diabetes mellitus: The DIMENSION trial

10.1177/1479164115621667Diabetes and Vascular Disease Research133192 - 20

Identification of novel breast cancer risk loci

It has been estimated that >1,000 genetic loci have yet to be identified for breast cancer risk. Here we report the first study utilizing targeted next-generation sequencing to identify single-nucleotide polymorphisms (SNP) associated with breast cancer risk. Targeted sequencing of 283 genes was performed in 240 women with early-onset breast cancer (≤40 years) or a family history of breast and/or ovarian cancer. Common coding variants with minor allele frequencies (MAF) >1% that were identified were presumed initially to be SNPs, but further database inspections revealed variants had MAF of ≤1% in the general population. Through prioritization and stringent selection criteria, we selected 24 SNPs for further genotyping in 1,516 breast cancer cases and 1,189 noncancer controls. Overall, we identified the JAK2 SNP rs56118985 to be significantly associated with overall breast cancer risk. Subtype analysis performed for patient subgroups defined by ER, PR, and HER2 status suggested additional associations of the NOTCH3 SNP rs200504060 and the HIF1A SNP rs142179458 with breast cancer risk. In silico analysis indicated that coding amino acids encoded at these three SNP sites were conserved evolutionarily and associated with decreased protein stability, suggesting a likely impact on protein function. Our results offer proof of concept for identifying novel cancer risk loci from next-generation sequencing data, with iterative data analysis from targeted, whole-exome, or whole-genome sequencing a wellspring to identify new SNPs associated with cancer risk. Cancer Res; 77(19); 5428-37. ©2017 AACR.Claire Hian Tzer Chan, Prabhakaran Munusamy, Sau Yeen Loke, Geok Ling Koh, Edward Sern Yuen Wong, Hai Yang Law, Chui Sheun Yoon, Min-Han Tan, Yoon Sim Yap, Peter Ang and Ann Siew Gek Le

Inherited breast cancer predisposition in Asians: Multigene panel testing outcomes from Singapore

10.1038/npjgenmed.2015.3npj Genomic Medicine11500

Randomized Controlled Trial Comparing Drug-coated Balloon Angioplasty versus Conventional Balloon Angioplasty for Treating Below-the-Knee Arteries in Critical Limb Ischemia: The SINGA-PACLI Trial

Background: There is a paucity of randomized trials demonstrating superior efficacy of drug-coated balloon angioplasty (DCBA) compared with conventional percutaneous transluminal angioplasty (PTA) for below-the-knee arterial disease in patients with critical limb ischemia.Purpose: To compare DCBA versus PTA for below-the-knee lesions in participants with critical limb ischemia through 12 months.Materials and Methods: In this prospective, randomized, two-center, double-blind superiority study, participants with critical limb ischemia with rest pain or tissue loss with atherosclerotic disease in the native below-the-knee arteries were randomly assigned (in a one-to-one ratio) to DCBA or PTA after stratification for diabetes and renal failure between November 2013 and October 2017. The primary efficacy end point was angiographic primary patency at 6 months analyzed on an intention-to-treat basis. Secondary end points through 12 months were composed of major adverse events including death and major amputations, wound healing, limb salvage, clinically driven target-lesion revascularization, and amputation-free survival. Primary and binary secondary end points, analyzed by using generalized-linear model and time-to-event analyses, were estimated with Kaplan-Meier survival curves and hazard ratios (Cox regression).Results: Seventy participants (mean age, 61 years 6 10 [standard deviation]; 43 men) in the DCBA group and 68 (mean age, 64 years 6 10; 50 men) in the PTA group were evaluated. The percentage of patients with angiographic primary patency at 6 months was 43% (30 of 70) in the DCBA group and 38% (26 of 68) in the PTA group (P=.48). Through 12 months, the percentage of deaths was similar: 21% in the DCBA group and 16% in the PTA group (P=.43). Amputation-free survival rate assessed with Kaplan-Meier curves differed through 12 months: 59% (41 of 70) in the DCBA group compared with 78% (53 of 68) in the PTA group (P=.01).Conclusion: In participants with critical limb ischemia, the drug-coated balloon angioplasty group and the conventional percutaneous transluminal angioplasty group had similar primary patency rates at 6 months after treatment of below-the-knee arteries. Amputation-free survival rates through 12 months were higher in the percutaneous transluminal angioplasty group. (C) RSNA, 2021Cardiovascular Aspects of Radiolog

Contractile and vasorelaxant effects of hydrogen sulfide and its biosynthesis in the human internal mammary artery

10.1124/jpet.107.133538Journal of Pharmacology and Experimental Therapeutics3242876-882JPET

Predictive factors for BRCA1 and BRCA2 genetic testing in an asian clinic-based population

10.1371/journal.pone.0134408PLoS ONE107e013440